Inhalation-Type Pharmaceutical Composition for Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, such as levodopa and dopamine agonists, face challenges including tolerance, side effects, and inconvenience for patients with dysphagia or tremors, who need to take multiple tablets daily.
Innovation Solution
An inhalation-type pharmaceutical composition combining hydrogen gas with atomized medications like levodopa, sinemet, and dopamine agonists, where the hydrogen gas concentration can range from 2 to 96%, enhancing absorption and convenience by using a mixture generated from electrolyzed water or a hydrogen bottle, along with a second gas to adjust concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If patients take multiple tablets daily (levodopa, sinemet, atropine sulfate, scopolamine, dopamine agonist, bromocriptine mesylate, selegiline, carbidopa, entacapone) to treat Parkinson's disease, then the curative effect is improved, but the ease of operation deteriorates due to the burden of taking multiple tablets
Solution Approach 1:
The patent combines multiple Parkinson's disease medications (levodopa, carbidopa, entacapone, dopamine agonists, and anticholinergics) into a single inhalation-type pharmaceutical composition. This merging of multiple drugs into one administration form eliminates the need for patients to take multiple separate tablets, thereby improving ease of operation while maintaining the comprehensive curative effect of the drug combination.
Solution Approach 2:
The patent delivers the pharmaceutical composition through inhalation using a nebulizer or similar aerosol-generating device. This pneumatic delivery system transforms the medication into a breathable aerosol form, allowing the combined drug mixture to be administered conveniently through a single inhalation act, thus resolving the contradiction between comprehensive treatment and ease of administration.
2Reliability
If conventional tablets are used for Parkinson's disease treatment, then the curative effect is achieved, but the ease of operation deteriorates for patients with dysphagia or tremors
Solution Approach 1:
The patent converts the pharmaceutical composition into an inhalable aerosol form using pneumatic nebulization technology. This delivery method bypasses the need for swallowing tablets, making it suitable for patients with dysphagia. The aerosol particles can be inhaled directly into the respiratory system, providing an alternative administration route that maintains curative effect while eliminating the operational difficulty for patients with swallowing or hand coordination problems.
Solution Approach 2:
The patent transitions the medication from the traditional oral solid tablet form to an aerosol suspension that can be inhaled through the respiratory system. This dimensional change in administration route (from gastrointestinal to respiratory) provides a new pathway for drug delivery that is particularly beneficial for patients who cannot swallow tablets, thereby resolving the contradiction between achieving curative effect and ease of operation.
3Reliability
If multiple tablets are administered to improve curative effect, then the treatment effectiveness is improved, but the device complexity increases due to needing multiple tablets and administration steps
Solution Approach 1:
The patent combines multiple Parkinson's disease medications (levodopa, carbidopa, entacapone, dopamine agonists, and anticholinergics) into a single inhalation-type pharmaceutical composition. This merging of multiple drugs into one administration form eliminates the need for patients to take multiple separate tablets, thereby improving ease of operation while maintaining the comprehensive curative effect of the drug combination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhalation-type composition provides improved absorption and convenience, reducing harmful radicals in the body while offering better curative effects for Parkinson's disease with reduced side effects and dosage requirements.
Implementation Method 1
provides the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen
Implementation Method 2
increases the absorption effect of the medicine for the patient by using an atomized medicine
Implementation Method 3
the first gas is a gas mixture of hydrogen and oxygen generated from electrolyzing water
Data Source
AI summary
The present invention provides an inhalation-type pharmaceutical composition for Parkinson's disease comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising levodopa, sinemet, atropine sulfate, scopolamine, dopamine agonist, bromocriptine mesylate, selegiline, carbidopa, entacapone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. Therefore, the present invention can provide a treatment for Parkinson's disease that combines the convenience of taking the medicine while also having better curative effects on the user.